

vanzacaftor/tezacaftor/deutivacaftor film-coated tablets (Alyftrek®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2800	for the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. SMC restriction: patients aged 6 years and older who have at least one F508del mutation in the CFTR gene.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	09/03/2026	07/05/2026

Other Decision Specified :

Web Link : <https://scottishmedicines.org.uk/media/9886/vanzacaftor-alyftrek-abb-final-feb-2026-for-website.pdf>

zilucoplan solution for injection in pre-filled syringe (Zilbrysq®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2830	as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.	Not routinely available as not recommended for use in NHS Scotland	09/03/2026	18/02/2026

Other Decision Specified :

Web Link : <https://scottishmedicines.org.uk/media/9888/zilucoplan-zilbrysq-final-feb-2026-for-website.pdf>

vorasidenib film-coated tablets (Vorango®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2844	for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and paediatric patients 12 years and older, who are not in need of immediate chemotherapy or radiotherapy following surgical intervention.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	09/03/2026	07/05/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9887/vorasidenib-vorango-final-feb-2026-for-website.pdf				
omaveloxolone hard capsules (Skyclarys®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2845	for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.	Not routinely available as not recommended for use in NHS Scotland	09/03/2026	18/02/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9893/omaveloxolone-skyclarys-final-feb-2026-for-website.pdf				

seladelpar capsules (Livdelzi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2899	for the treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.	Not routinely available as not recommended for use in NHS Scotland	09/03/2026	18/02/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9885/seladelpar-livdelzi-resub-final-feb-2026-for-website.pdf				
isatuximab concentrate for solution for infusion (Sarclisa®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2914	in combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.	Not routinely available as not recommended for use in NHS Scotland	09/03/2026	18/02/2026
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9889/isatuximab-sarclisa-non-sub-final-feb-2026-for-website.pdf				

pembrolizumab concentrate for solution for infusion (Keytruda®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2915	in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma.	Not routinely available as not recommended for use in NHS Scotland	09/03/2026	18/02/2026
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9891/pembrolizumab-keytruda-non-sub-final-feb-2026-for-website.pdf				
sacituzumab govitecan powder for concentrate for solution for infusion (Trodelvy®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2916	as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.	Not routinely available as not recommended for use in NHS Scotland	09/03/2026	18/02/2026
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/9884/sacituzumab-govitecan-trodelvy-non-sub-final-feb-2026-for-website.pdf				